口服による低血糖薬に対する子宮内被曝の影響
K Piacquadio1, D R Hollingsworth, H Murphy
1Department of Obstetrics and Gynecology, Naval Hospital, San Diego, California.
Lancet (London, England)
|October 5, 1991
まとめ
妊娠中に服用された経口低血糖剤は,乳児における先天性異常および新生児低血糖症の発生率が高いことと関連していました. これらの発見を,より大きな将来性研究で確認するために,さらなる研究が必要である.
科学分野:
- 産婦人科と産婦人科を担当しています.
- 新生児医学 新生児医学
- エンドクリノロジー エンドクリノロジー
背景:
- 経口低血糖剤は,非インスリン依存性糖尿病 (NIDDM) の妊婦によって時々使用されます.
- 以前の報告では,これらの薬剤と先天性異常との潜在的な関連が示唆されています.
研究 の 目的:
- 胚形成中の経口低血糖薬への曝露と,NIDDMの母親の乳児における先天性異常との関連性を調査する.
- 新生児のアウトカムを評価するために,薬物曝露に関連して,不発症,高bilirubinemia,多細胞血症,高粘度,低血糖を含む.
主な方法:
- 経口低血糖薬に曝露した20人の妊娠中のNIDDM女性と,曝露していない40人のマッチングしたコントロールを比較したケース・コントロール研究.
- 胎児の先天性異常や新生児合併症の追跡調査.
主要な成果:
- 口服による低血糖薬に曝露した乳児は,対照群 (15%) に比べて,先天性不発症の割合 (50%) が著しく高かった.
- 曝露された乳児の25%に耳の変形が認められた.
- ハイパービリルビレミア,ポリシテミア,高粘度,重度の新生児長期低血糖症の発生率の増加は,暴露されたグループで観察されました.
結論:
- 胎児の発達中の経口低血糖薬への曝露は,先天性欠陥および新生児低血糖症のリスクの増加と関連しているようです.
- これらの発見を確認し,母親の代謝制御から薬物の効果を区別するために,より大きな前向きな研究が必要である.
さらに関連する動画
関連する概念動画
Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...


